메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten

- Accretive Commercialization Services Agreement covering six mature assets across critical care, cardiovascular, and metabolic disease leveraging Everest's existing commercial organization- Exclusive Greater China license to develop and commercialize Lerodalcibep, a novel, small protein-binding, third-generation PCSK9 inhibitor that adds to the Company's late-stage product pipeline- Together, these agreements drive financial and strategic synergies, improve utilization and productivity of our existing commercial platform, and strengthen commercial capabilities and life-cycle management, whi
- 김갑성 기자
- 2025-12-11 23:57
Datasea Announces Breakthrough in Acoustic-Driven Brain-Computer Interface Technology

Developing Healthcare and Intelligent Interaction Through Core Acoustic Innovation BEIJING, Dec. 11, 2025 -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a global technology enterprise specializing in acoustic high-tech innovations and AI multimodal digital solutions, today announced progress in its research and development efforts related to brain–computer interfaces (BCI) technologies. The Company's Real-Time Closed-Loop Vibration-Enhanced BCI System and Acoustic-Coupled EEG Signal Enhancement System have successfully completed engineering-sta
- 김갑성 기자
- 2025-12-11 22:30
ProPharma Expands Operations with New Office in Hyderabad

Modern workspace supports continued growth and innovation RALEIGH, N.C., Dec. 11, 2025 -- ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry and a portfolio company of Odyssey Investment Partners, today announced the official inauguration of its new office in Hyderabad, India, on November 17, 2025. Strategically located in Mindspace, at the heart of Hyderabad's technology corridor (HITEC City/Madhapur), the new office places ProPharma among the world's leading Global Capability Centers (GCCs) in the phar
- 김갑성 기자
- 2025-12-11 21:10
HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025

[ 메디채널 김갑성 기자 ] International debut underscores emerging role for macrophage checkpoint therapy in gastric cancer, triple-negative breast cancer, and other hard-to-treat solid tumors TAIPEI, SHANGHAI, AND SAN FRANCISCO, Dec. 11, 2025 -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that new clinical data from its flagship macrophage-checkpoint program, HCB101, has been selected for a mini oral presentation at the ESMO Immuno-Oncology Congress 2025 in London, U
- 김갑성 기자
- 2025-12-11 21:00
MATELASER W1 REGEN: The Lightest 24g and Highest 5,100 mW/cm² Wearable Red Light Therapy Device Debuts on Kickstarter

MIAMI, Dec. 11, 2025 -- MATELASER, INC., a pioneer in mobile laser therapy, today announced the official launch of its global crowdfunding campaign for the W1 REGEN, a breakthrough device that brings clinic-grade laser therapy into an ultra-miniature 24g wearable form. Priced at just $99, W1 REGEN officially breaks the cost barrier for true medical-grade photobiomodulation, marking a major step forward in the consumerization of laser therapy. A New Category: Pocket-Sized, Deep-Tissue Laser Therapy Unlike large LED-panel "red light masks" and low-irradiance consumer gad
- 김갑성 기자
- 2025-12-11 20:30
The 2nd International Cerebro-cardiovascular Medical Innovation Summit (ICMIS 2025) Opens in Hong Kong: AI Technology and Digital Health Usher in a New Chapter of Translational Medicine.

HONG KONG, Dec. 11, 2025 -- Cerebro-cardiovascular conditions have continued to pose a public health burden. The convergence of population ageing and lifestyle risk factors has made "earlier detection, earlier intervention, and accessible and affordable prevention and management" a common challenge for global healthcare systems. Concurrently, the rapid development of technologies such as Artificial Intelligence (AI), digital health platforms, and medical imaging has brought new possibilities for related risk assessment, early screening, risk stratification, and precision therapy. Ho
- 김갑성 기자
- 2025-12-11 19:19
Life-Space Fiber Jelly: The Fiber Fix Modern Guts Have Been Waiting For

[ 메디채널 김갑성 기자 ] The smarter, tastier way to meet your daily fiber needs, powered by Litesse for smooth digestion and real gut results. KUALA LUMPUR, Malaysia, Dec. 11, 2025 -- In a world where convenience often outweighs nutrition, Life-Space Fiber Jelly steps in the jelly way to gut health and lightness. The interactive showcase held in Kuala Lumpur, invited attendees to craft their own wholesome oat bowls, pick up mindful nutrition tips, and discover how Life-Space Fiber Jelly, a delicious, jelly-based supplement gives fiber a modern makeover — transforming daily nutrition into a m
- 김갑성 기자
- 2025-12-11 17:57
Bowtie Announces New Headquarters - "Bowtie Life Insurance Tower"

HONG KONG, Dec. 11, 2025 -- Bowtie, Hong Kong's first virtual insurer[1], announces the strategic relocation of its headquarters to 68 Johnston Road, Wan Chai. Effective 1 February 2026, the building will be officially renamed "Bowtie Life Insurance Tower" ("Bowtie Tower"). Located in a prime and highly visible district, this milestone marks Bowtie's growth from a home-grown startup into Hong Kong's leading digital insurer, reaffirming its long-term commitment to the city. To support its continuous business growth, Bowtie has signed a five‑year lease spanning seven
- 황정호 기자
- 2025-12-11 14:26
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO

[ 메디채널 김갑성 기자 ] Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion dollar pillar of cancer care, hampered by widespread resistance The study achieved its objective, as the new Q6W extended dosing interval produced encouraging anti-tumor efficacy and immunological data in prior immune-oncology refractory or relapsed patients including anti-PD- (L)1 checkpoint inhibitor, with improved safety, compared to the prior Q2W schedule Th
- 김갑성 기자
- 2025-12-11 14:12
OTR Therapeutics and Zealand Pharma enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases

[ 메디채널 김갑성 기자 ] Collaboration will combine Zealand Pharma's expertise in obesity and metabolic health with OTR Therapeutics' proprietary oral small-molecule platform and strong drug discovery capabilities, to discover and develop novel therapeutics for multiple targets in metabolic diseases OTR Therapeutics will receive an initial upfront payment of USD 20 million, which may increase to USD 30 million under certain pre-agreed conditions, and is eligible for potential preclinical, development, regulatory, and commercial milestone payments, for a potential total consideration of up to USD ~2
- 김갑성 기자
- 2025-12-11 14:00

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 22시 40분